Kevin Patrick Danahy - Feb 14, 2022 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role: Chief Commercial Office
Signature: /s/ Kenneth B. Stratton, as Attorney-in-Fact
Stock symbol: PLSE
Transactions as of: Feb 14, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/22/2022, 04:11 PM
Next filing: Mar 24, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PLSE	Stock Option (right to buy)	Award		+300K			300K	Feb 14, 2022	Common Stock	300K	$6.41	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option was granted on February 14, 2022 under the Issuer's 2017 Inducement Equity Incentive Plan. The shares subject to the option are subject to a mix of time-based and performance-based vesting criteria. 200,000 shares will vest in equal annual installments over the following four years on the anniversary of the grant date and 100,000 shares will vest in two equal annual installments on the third and fourth anniversaries of the grant date, in all cases, subject to the Reporting Person's continued service through each vesting date.
F2	Not applicable.

Content

The option was granted on February 14, 2022 under the Issuer's 2017 Inducement Equity Incentive Plan. The shares subject to the option are subject to a mix of time-based and performance-based vesting criteria. 200,000 shares will vest in equal annual installments over the following four years on the anniversary of the grant date and 100,000 shares will vest in two equal annual installments on the third and fourth anniversaries of the grant date, in all cases, subject to the Reporting Person's continued service through each vesting date.

Not applicable.